多西紫杉醇联合草酸铂二线治疗晚期非小细胞肺癌的临床观察

Clinical observation of docetaxel combined with oxaliplatin as the second-line therapy in advanced NSCLC

目的:观察多西紫杉醇联合草酸铂二线治疗晚期非小细胞肺癌的疗效和毒性。方法:30例一线治疗失败的晚期非小细胞肺癌患者采用多西紫杉醇+草酸铂联合方案化疗3个周期后,按照WHO实体瘤疗效判定标准评价疗效,按NCICTC3.0常见毒副反应分级标准评价毒副反应。结果:30例患者均完成3个周期化疗,完全缓解(CR)1例,部分缓解(PR)7例,总有效率26.7%。Ⅲ/Ⅳ度白细胞减少为16.7%,Ⅲ度血小板减少为3.3%,Ⅲ度周围神经毒性为16.7%,其它副反应轻微。结论:多西紫杉醇联合草酸铂联合方案对一线失败的晚期非小细胞肺癌有一定的疗效,毒副反应较低。

Objective.To observe the efficacy and toxicily of docetaxel combined with oxaliplatin as the second line therapy for advanced non-small-cell lung carcinoma （ NSCLC ）. Methods： Thirty NSCLC patients who had failed in first-line chemotherapy received docetaxel and oxaliplatin chemotherapy and the clinical response was assessed after three cycles. Results：Among 30 patints,one patient achieved complete response（CR） and seven patients had partial response（PR）. The overall response rate（RR） was 26. 7%. 16. 7% patients had grade Ⅲ/Ⅳ leucopenia, 3.3% patients had grade m thrombocytopenia and 16. 7% patients had grade m neurotoxicity. Conclusion：The regimen of docetaxel combined with oxaliplatin is more effective in the treatment of advanced non-small cell lung cancer and its toxicily reactions are tolerable.